Pharmesis International (SGX:BFK) completed the acquisition of the remaining 19% stake it did not own in Sichuan Longlife Pharmaceutical, a filing with the Singapore Exchange said on Monday.
Following the acquisition, Sichuan has become a wholly owned subsidiary of the company.
Pharmesis first announced the deal on Sept. 23, agreeing to acquire the balance stake for 2.8 million yuan.
Shares of Pharmesis surged over 14% in recent trading.
Price (SGD): S$0.20, Change: S$+0.025, Percent Change: +14.29%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.